Innovation

A new foundation for future talent

We’re partnering with N.C. A&T to launch a collaborative biotechnology learning center

April 22, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

researcher with full protection gear.

Building the workforce of tomorrow means investing in the students of today. That’s why we’ve partnered with North Carolina Agricultural and Technical State University (N.C. A&T) — the largest historically Black college and university in the U.S. — to launch the Merck Biotechnology Learning Center.

“We’re pleased to launch this new collaboration with an institution that precisely aligns to our company priorities to invest in the growth and delivery of innovative health solutions and strong values around diversity and inclusion,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “Together we can fuel the growth of talent for our company and the biotechnology industry overall.”

Located in the home state of our Durham and Wilson manufacturing sites, the 4,025 square-foot facility will enhance academic programming and training for biotechnology careers for N.C. A&T students and provide advanced discovery opportunities through its classroom space, process laboratory and state-of-the-art biopharmaceutical manufacturing equipment.

“This collaboration signifies a union between academia and industry, and a commitment to excellence, innovation and the advancement of scientific knowledge,” said Tonya Smith-Jackson, Ph.D., provost and executive vice chancellor of academic affairs for N.C. A&T.

The collaboration also signifies an investment in the community’s future by expanding local and statewide bioeconomy initiatives. It’ll also help to expand talent and recruitment opportunities for our company and offer vaccine manufacturing process training for new and existing employees. 

“The Merck Biotechnology Learning Center will provide opportunities for N.C. A&T students to look inside the biopharmaceutical industry and understand what a career in this space looks like. Through our joint initiative with N.C. A&T, we’re developing new and innovative ways to build a pipeline of talent here in North Carolina and beyond.” 

  • Amanda Taylor
    Vice president and Durham plant manager
Innovation

Humans, animals and the environment – our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

little girl hugging a white dog

The health of humans, animals and the environment are all interconnected. When the health of one is at risk, the health of all may be at risk.   

We see it in diseases transferred between animals or insects and humans (called zoonotic and vector-borne diseases) such as rabies, Lyme disease, West Nile virus, swine flu and Ebola, among others. We also see it in the growing threat from antimicrobial resistance (AMR), which occurs when bacteria mutate in ways that make the medicines (antimicrobials) used to treat infections ineffective, or when these medicines are used inappropriately to treat viral infections. Or, in diseases in food-producing animals, jeopardizing global food security.

Our increasing vulnerability to such new health challenges has led to a focus on “One Health” — an integrated approach to addressing human, animal and environmental health for the benefit of all.

What is One Health?

One Health is the collaborative approach across multiple disciplines — working locally, regionally, nationally and globally — to prevent, detect and respond to health issues at the interfaces between humans, animals and the environment.

illustration of lots of people working together

It requires collaboration among doctors, veterinarians, nurses, public health practitioners, epidemiologists, agricultural workers, ecologists, wildlife experts, and industry as well as policymakers, communities and even pet owners.

“No one person, organization or sector can address these issues alone. Identifying and responding to growing health challenges requires teamwork,” says Holger Lehmann, DVM, Ph.D., VP, pharmaceuticals research and development, Merck Animal Health.

But what has led to these increasing population health threats?

Why are we more vulnerable to new health challenges?

Society has undergone major changes over the past century. While technology, increased mobility, industrialization, urbanization and globalization have advanced human, animal and environmental health in many ways, they’ve also made us more vulnerable to new health challenges.

For example, according to the Centers for Disease Control and Prevention, every year, millions of people and animals around the world are affected by zoonotic diseases. Scientists estimate that around 60% of emerging infectious diseases that are reported globally come from animals, both wild and domestic. Over 30 new human pathogens have been detected in the last 3 decades, 75% of which have originated in animals.

They can be spread in a number of ways, including direct or indirect contact, vector-borne, foodborne or waterborne. In fact, foodborne pathogens cause millions of cases of sporadic illness and chronic complications, as well as large and challenging outbreaks in many countries and between countries.

In addition, increased exposure to new viruses/bacteria combined with excessive and/or inappropriate use of medicines is causing a rise in AMR. Worldwide, an estimated 4.95 million people died with drug-resistant bacterial infections in 2019, and 1.27 million of these deaths were directly caused by antimicrobial resistance (AMR).

Three main factors are fueling these population health threats, increasing the probability and speed of spreading diseases. They are:

farmland landscape with livestock

Changes in climate and land use

Deforestation and other disruptions in environmental conditions can provide new opportunities for diseases to develop.

Exponential population growth and expansion into previously uninhabited areas

More people are living in close connection to their companion animals, and in some cases, closer to wild and domestic animals.

world map with lines showing increasing mobility

Increased international mobility

People, animals and animal products are moving more frequently, easily and widely than ever before.

Our commitment to One Health

With deep expertise in both human and animal health and a commitment to our shared environment, our company is well-positioned to be a leader in the One Health approach.

“We recognize the issues — such as zoonotic and infectious diseases and food safety and security — are interrelated,” says Ian Tarpey, Ph.D., VP, biological research and development, Merck Animal Health. “Our Animal Health and Human Health teams will continue to collaborate to discover and develop preventative solutions for existing and emerging diseases in animals and people.”

Our One Health approach focuses on many areas, including:

icon
Disease prevention

We remain focused on discovering and developing vaccines and technologies to help prevent both human and animal diseases.

icon
Surveillance and monitoring

We’re committed to advocating for and participating in scientifically based surveillance monitoring systems to better understand, track and predict health-related issues.

icon
Respecting our environment

We support science-based, environmentally sound international and national programs to address the challenges to environmental health.

icon
Innovation

Our human and animal health research laboratories collaborate in antimicrobial and vaccine research in many ways including sharing enabling technologies, expertise and evaluation of external opportunities. We’re also investing and developing predictive, monitoring and diagnostic technologies to help animal caretakers make data-driven evaluations of an animal’s health status and optimize their animals’ health and well-being.

icon
Stewardship of essential medicines

We’re playing a leading role in addressing AMR by not only discovering and developing medicines and vaccines to treat and prevent infectious diseases in humans and animals but also supporting responsible use of these products.

icon
Safe and sustainable food supply

We continue to work on developing vaccines and other tools to prevent animal disease to ensure a safe, nutritious, sustainable food supply, and we’ve implemented surveillance initiatives to enable more accurate risk profiling, early disease detection and individualized diagnosis/treatment decisions in livestock.

two dogs running on the grass

The science of healthier animals

We build strong partnerships in an effort to improve the health of animals around the world, and approach our work with a deep sense of responsibility — to our customers, consumers, animals, society and the planet.

Our work to promote optimal health continues

“One Health recognizes the interconnectedness of human, animal and environmental health, acknowledging that the well-being of each is intricately linked. By embracing a collaborative approach, we can effectively address the complex challenges and promote optimal health for both humans and animals.”

– Dr. Jenelle Krishnamoorthy, VP, global public policy

Innovation

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

trees with water

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Paul Scott, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Andrew (Drew) Otoo, PharmD, president of global vaccines from 2022-2025 and current regional president, Merck. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.

Innovation

Teaming up with Eisai to help fight cancer

How we're leveraging each other’s unique strengths to help advance cancer research

April 10, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientists wearing masks working in a lab

Combining two ambitious cancer research teams to form a united front to help people with cancer

It’s sometimes said that the whole is greater than the sum of its parts. That’s why in 2018 we teamed up with Eisai, a global pharmaceutical company headquartered in Japan, to work together to advance cancer research.

“Combining Merck’s leadership in immuno-oncology with Eisai’s strengths in small molecules allows us to advance a combination approach that has the potential to help more people living with challenging cancers,” says Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories.

Dr. Takashi Owa

"There's still an unmet need for many patients with cancer. These patients and their families are in need of more treatment options, and this remains at the forefront of our collaborative efforts."

Dr. Takashi Owa

Vice president, chief medicine creation and chief discovery officer, oncology business group, Eisai

Together, we’re striving to drive cancer science forward, and this shared vision has led to multiple clinical trials investigating the companies’ combination treatment option in various tumor types.

Through this comprehensive approach, we’ve been expanding the joint clinical program to help as many cancer patients as possible.

Why did you decide to go into oncology research?

“My decision was very personal,” says Owa. “At the age of six, my grandmother passed away from gastric cancer. I couldn’t fully process what had happened to her at that young age. It wasn’t until I entered junior high school that I began to understand the toll cancer had taken on her, which motivated me to learn about cancer and find my passion in cancer research.”

Lubiniecki’s experience was also very personal.

“Watching my mother recover from breast cancer while I was in high school exposed me to the challenges patients face when battling cancer. These experiences inspired me to ultimately pursue oncology,” explains Lubiniecki. “Oncology clinical research offers an opportunity to impact the practice of medicine greatly.”

Looking to the future

“I’m proud of what we’ve been able to accomplish together in our pursuit to investigate additional options for patients across a broad range of cancer types through our robust clinical development program,” says Lubiniecki.

Owa is optimistic about the progress the two teams have made together. “We’ve already seen encouraging anti-tumor activity in several difficult-to-treat cancers, which has led to multiple milestones to date,” he says. “As we continue to enhance our knowledge and scientific evidence through our ongoing clinical research efforts, together, we aim to give patients and their families hope.”

Lubiniecki believes that collaborations are important to continuing to advance cancer research and improve the outcomes of people with cancer.

Dr. Greg Lubiniecki smiling

“A collaborative approach is key to advancing science and making strides in drug discovery and development.”

Dr. Gregory Lubiniecki

Vice president, global clinical development, Merck Research Laboratories

“Working with others driven by the same patient-centric goals can yield innovations and is imperative to continued progress in improving patient care,” says Lubiniecki. “I’m thrilled to be a part of this collaboration as we continue to advance and expand the clinical trial program.”

Innovation

How Merck scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

March 29, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

collage of photos of scientists working in labs

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at Merck has been foundational in how we treat metastatic disease, or cancer that has spread.”

  • Dr. Jane Healy
    Vice president and head of oncology early development, Merck Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, our researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through our own research and external collaborations, we’ve developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

  • Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, we’re investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.

    We’re also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  • Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, our scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.

    Similarly, we’re pursuing research that enhances the ability of T cells to recognize and attack tumors.
  • Impacting pathways that can drive cancer growth: We’ve identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, we’re evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

"We're committed to investing in novel research where scientific opportunity and medical need converge. "

— Jane Healy

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,250 ongoing clinical trials, which include more than 1,600 trials evaluating combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Healy.

Gloved hand handling a small laboratory device labeled

Learn more about our oncology pipeline

Innovation

Our Q4 and full-year 2023 earnings report

February 1, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

people wearing goggles using ipad

Merck’s (NYSE: MRK) Q4 and full-year 2023 results reflect sustained growth across oncology and vaccines. Our company announced Q4 worldwide sales of $14.6 billion, an increase of 6% from Q4 2022. Full-year 2023 worldwide sales were $60.1 billion, an increase of 1% from full-year 2022. ​

“2023 was another very strong year for Merck. I am extremely pleased by the progress we’ve made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than 500 million people with our medicines last year alone, over half of which were donations, including through our program to treat river blindness,” said Rob Davis, chairman and chief executive officer. “We also made investments of approximately $30 billion in research and development in our ongoing effort to discover, develop and collaborate to propel the next generation of impactful innovations. As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team.”​

Merck anticipates full-year 2024 worldwide sales to be between $62.7 billion and $64.2 billion.​

Take a look at the infographic below for more details on Q4 and full-year 2023 results.

Download infographic

2023 q4 financial result
Innovation

The Wall Street Journal names Merck among top 10 best-managed companies 

We’re proud to be recognized for our strong performance and unwavering commitment to patients

January 11, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

the wall street journal 2023

Our company has been recognized for our leadership and strong performance powering the work we do for patients and everyone who depends on us. We were named No. 10 on The Wall Street Journal’s list of the 250 best-managed publicly traded U.S. companies in 2023, advancing 78 places from the previous year.

Rob Davis

“This recognition reaffirms our strategic focus, innovation, hard work and collective, unwavering commitment to our purpose of saving and improving lives each and every day.”

— Rob Davis

Chairman and chief executive officer

“To make the list of The Wall Street Journal’s 250 best-managed companies is quite an honor,” Davis said, “and to be ranked in the top 10 is especially exciting and humbling.” 

This year, nearly 800 companies were scored. Placement on the list is determined by a company’s strength in five components:

  1. Customer satisfaction
  2. Employee engagement and development
  3. Innovation
  4. Social responsibility
  5. Financial strength

We placed first in customer satisfaction and were one of seven companies to score in the top 20% in each of the five components.

“Customer satisfaction is directly tied to the innovation we bring and the benefit we can deliver for patients,” Davis told The Wall Street Journal.

Top ranking for corporate citizenship 

In addition to our Wall Street Journal recognition, we’re deeply honored to be ranked No. 1 on Newsweek’s 2024 list of America’s Most Responsible Companies. This marks our first time in the lead spot, a distinction that affirms our steadfast commitment to operating responsibly and doing good for people and the planet.  

Innovation

Harnessing innovative technology in drug discovery

Merck scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives

November 16, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist in the lab

Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow. 

Merck Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.

Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.

“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”

— Adam Weinglass

Executive director in quantitative biosciences
Innovation

Breaking new ground in the UK

We’re accelerating our global efforts and capabilities with our new London Discovery Research Centre and U.K. headquarters

November 10, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

3 people with hard hats breaking ground

Using the power of leading-edge science to help save and improve lives means tapping into scientific talent around the world. That’s why we’re proud to break ground on our new London Discovery Research Centre and U.K. headquarters.

The high-profile site — located opposite King’s Cross Station in the heart of London’s Knowledge Quarter, an impressive cluster of academic, scientific and technological institutions — will be an impactful addition to our growing network of research facilities.

“Our talented discovery scientists in London are an integral part of our global research network.”

  • Dean Li
    President of Merck Research Laboratories

“Patients around the world are waiting for innovations that will help confront the tremendous burden of disease they face, and the kind of world-class scientific exploration this facility will enable is how we accelerate those innovations,” Li added.

Slated to open in 2027, the 270,000-square-foot, 10-story facility will bring together all our U.K. colleagues to help drive medical advances against some of today’s greatest health challenges.  

“With the benefit of London’s thriving life sciences ecosystem and Knowledge Quarter right on our doorstep, I’m excited about the collaboration opportunities, building toward an exciting new chapter, and what this represents for employees and our partnership with the local community and beyond,” said Ben Lucas, managing director, U.K. and Ireland.

Innovation

Merck’s legacy of antimicrobial innovation and action

Delivering on our commitment to fight infectious diseases for more than a century

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist working with liquid

For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to fight infectious diseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR

1930s

Merck Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.

vials with background of industrial complex

1940s

In collaboration with Rutgers University, we developed streptomycin, the first antibiotic effective against tuberculosis. We also helped to develop one of the first methods for mass production of penicillin.

scientist taking out trey of vial

1950s & 1960s

We developed multiple novel methods to prevent infectious diseases, including pediatric vaccines.

scientist working with equipment

1970s & 1980s

We received U.S. Food and Drug Administration (FDA) approval for two vaccines, as well as three antibiotics that treat a variety of bacterial infections.

doctor holding patients right arm

1990s & 2000s

Merck received U.S. FDA approval for two antifungals, as well as licenses for two vaccines.​

2002

With resistance to antibiotics developing faster through people, animals and the environment, we launched one of the world’s largest and longest-running antimicrobial resistance surveillance studies. Called the Study for Monitoring Antimicrobial Resistance Trends (SMART), the program enables researchers to monitor and identify trends in the development of AMR.

2010s

We launched an Antimicrobial Stewardship (AMS) Investigator Initiated Studies program, supporting investigator-based, peer-reviewed research supporting the implementation of AMS principles across the globe, with over 20% of studies occurring in low-and middle-income countries.

large building

2016

We created the Merck Exploratory Science Center in Cambridge, Massachusetts, focusing on the earliest stages of research into the underlying biology of human disease.

2016-2017

We supported the first United Nations high-level meeting on AMR and subsequent political declaration in 2016, which set policy action on AMR in motion.

As a next step, we joined the newly founded AMR Industry Alliance – a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help curb antimicrobial resistance.

AMR action fund logo

2020

Merck, along with a group of more than 20 leading biopharmaceutical companies, launched the AMR Action Fund to bring 2-4 new antibiotics to patients by the end of the decade.

2020s

Our staff have championed government actions to create supportive markets for antimicrobial innovation, including the PASTEUR Act in the U.S., inclusion of transferable exclusivity extensions in the EU pharmaceutical strategy, and other incentives around the world.

By collaborating with policymakers, Merck aims to improve appropriate antibiotic use globally.

cow drinking milk from bottle

Going forward

In recognition of our leadership in both human and animal health, Merck represents industry in the One Health Global Leaders Group on Antimicrobial Resistance, which advocates for a One Health approach to help ensure antibiotics remain an important tool in improving and maintaining human and animal health.